Navigation Links
Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
Date:10/8/2009

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Ph.D. chief executive officer, will present initial data supporting direct detection of DNA targets in human clinical samples during company presentations at the following conferences:

  • AdvaMed 2009 on Tuesday, October 13, 2009 at 10:00 a.m. Eastern Time at the Walter E. Washington Convention Center in Washington, D.C.
  • BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at 10:00 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego, California.

"The hallmark of Adnavance's direct detection technology is its simplicity; it doesn't require PCR, light detection, or sample pre-treatment. We are highly encouraged by our initial data supporting the utility of our technology and its potential for use in medium complexity laboratories," said Dr. White. "Our mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of its proprietary technology that allows direct-detection of DNA targets in human clinical samples. The Company is located in San Diego, CA. The Company's patented technology is based on the change in surface charge on a gold electrode when DNA targets hybridize with capture probes anchored to the electrode surface. The Company uses a microarray of electrodes in an electrochemical cell to detect the target DNA and the inherent ultra-sensitivity of electrochemical measurements obviates the need for target amplification used in current molecular-based tests. In addition, the electrochemical measurement simplifies the medical device and eliminates sample pre-treatment steps required for PCR-based tests. Adnavance scientists were the first to discover the surface charge phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

    Media Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com

SOURCE Adnavance Technologies Inc.


'/>"/>
SOURCE Adnavance Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
2. ReBuilder Medical Technologies, Inc. Hiring! Increases Staff by 40%
3. Wound Management Technologies Acquires Resorbable Orthopedics
4. Blue Belt Technologies, Inc. Closes Series A Financing
5. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
6. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
9. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
10. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
11. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today ... ended December 31, 2015, the Company achieved revenue of $8,195,839, ... same quarter in fiscal 2015. --> ... fiscal year 2016 was $2,068,635, or $.03 per share, up ... share, in the Q2 of fiscal year 2015. Gross margin ...
(Date:2/8/2016)... http://www.researchandmarkets.com/research/bcrl3s/labelfree ) ... "Label-Free Detection Market by Technology, Products, Applications ... to their offering. --> http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ...
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, ... that they are loved. This year, for more than 5.6 million Americans suffering with ... won't be enough to remind them of the lives they’ve led and the people they’ve ...
(Date:2/8/2016)... ... , ... If you are feeling that your clothes are a tad snug, ... the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are ... cancer, some of the leading causes of preventable death. February is heart health ...
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
Breaking Medicine News(10 mins):